2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
We had an amazing time seeing you all in person at conferences this past quarter. We accomplished a great deal these past three months—from sharing the randomized Disrupt PAD III Study results at SCAI 2022 to launching Shockwave M5+ across the globe. JSCAI also published two articles discussing peripheral IVL for treatment of calcified common femoral artery disease, and the mid-term outcomes from the randomized Disrupt PAD III Trial. Check out the latest in the PulsePoint newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
This year has been “chalk” full of good vibrations at Shockwave! We launched our most efficient IVL catheter yet, the faster-pulsing Shockwave M5+, and its effects have been helping patients with calcified PAD across the globe ever since. Our data also got deeper, with the Disrupt CAD III one-year data published in JSCAI, demonstrating Coronary IVL’s excellent safety and effectiveness outcomes at 30 days out to one year. We heard from physicians like Dr. B. Clay Sizemore on using Coronary IVL in a no-surgical-backup hospital, and Dr. Alexandra Lansky regarding gender disparities in cardiovascular disease. To top it all off, Fast Company recognized Shockwave as one of the World’s Most Innovative Companies for 2022. Check out all of this and more in the latest PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
Winter is coming… and fast but before we enter the final home stretch of the year, let’s recount the milestones of the recent quarter in the latest edition of the PulsePoint Newsletter. Shockwave hit the ground running this quarter by bringing on various IVL experts from across the globe to discuss all things calcium on the ChalkTalk Podcast Series. Shockwave also made headlines in CathLab Digest with several physician-authored perspectives about the role of the technology in clinical practice. And it was great to finally get back to live, in-person conferences like VIVA ’21, where the results from the first 752 patients in the Disrupt PAD III Observational Study were presented. Catch up on what you may have missed and don’t forget watch the CalciumMasterclass.com series finale!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
Shockwave has been making waves this summer! As you dive into this edition of the PulsePoint Newsletter, you’ll see that JACC: Cardiovascular Interventions published a trilogy of peer-reviewed publications highlighting Shockwave’s MOA, a pooled analysis of the 4 Disrupt CAD studies, and Disrupt PAD lll. Dive deeper and you’ll discover the incredible 10-webinar series called Calcium Masterclass that was launched at the beginning of the quarter. Explore how Shockwave was granted transitional pass-through reimbursement for Coronary IVL and proposed additional payment for hospital in-patient Coronary IVL cases performed in the United States. This PulsePoint has a lot to cover – recap the rest of the events and milestones from an exciting last quarter. But as you relax on your vacation, always stay on the pulse!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
PulsePoint is back! Bringing you a highlight reel of the most memorable moments, successes and key events of Q1 for both our coronary and peripheral technology. Most notably, Shockwave had a history-making moment in February of this year when we received FDA approval in the U.S. for Coronary IVL! Since then, we have seen many physicians achieving great success utilizing the technology. We also brought a new podcast, ChalkTalk, to life, and so much more we want to share with you. Check out the latest PulsePoint for the full scoop!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
PulsePoint Newsletter
Your first Shockwave IVL newsletter, PulsePoint, has arrived. We’re kicking off with an ambitious recap of 2020, celebrating key milestones and major events for our customers using our peripheral technology across the globe. Released on a quarterly basis moving forward, PulsePoint will be the one stop shop for all the latest news and updates throughout the year. We hope you enjoy our first global edition of PulsePoint.
Read More
Topics:
Peripheral IVL,
PulsePoint Newsletter